SOURCE: The Bedford Report

The Bedford Report

October 13, 2010 08:46 ET

Opportunities in Drug Manufacturing Industry as M&A Activity Increases

The Bedford Report Provides Analyst Research on Sanofi-Aventis and Johnson & Johnson

NEW YORK, NY--(Marketwire - October 13, 2010) -  In recent months the Major Drug Manufacturers industry has become a hotbed of Merger and Acquisition activity. As companies get larger and experience diminishing returns in their core business, they are showing their willingness to utilize their large resource pools to acquire smaller companies in a race to diversify themselves. Given the limited opportunities for meaningful acquisitions, the companies in stronger financial positions, and the willingness to act, stand to gain the most from such activities. The Bedford Report examines the outlook for companies in the Major Drug Manufacturers Industry and provides research reports on Sanofi-Aventis SA (NYSE: SNY) and Johnson & Johnson (NYSE: JNJ). Access to the full company reports can be found at:

In August, Sanofi-Aventis publically announced that it made an offer to acquire Genzyme Corp. for $69 per share in an all-cash transaction valued at about $18.5 billion. After Genzyme's continued refusal to accept the offer or negotiate, Sanofi-Aventis announced it had gone hostile with its offer this October and will take its offer directly to Genzyme shareholders. While Sanofi-Aventis is confident the deal will get done, Genzyme's board has urged shareholders not to tender their shares, calling the offer "inadequate and opportunistic." Genzyme went on to disclose that Sanofi-Aventis had privately indicated it would pay as much as $80/share for the company before it decided to go hostile with its original bid.

The Bedford Report releases regular market updates on the Major Drug Manufacturers Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us for free at and get exclusive access to our numerous analyst reports and industry newsletters.

Genzyme has indicated that the company has received indications of interest following preliminary communications with other major drug manufacturers, one of which being Johnson & Johnson, whom has been aggressively pursuing Merger & Acquisition opportunities as of late. Last week, Johnson & Johnson announced it has reached an agreement to move forward with its $34.30 per share offer for vaccine manufacturer, Crucell. Both companies said the deal will likely close in early 2011.

The Bedford Report provides Analyst Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at

Contact Information